According to Protalix BioTherapeutics 's latest financial reports the company's current earnings (TTM) are $9.69 M. an increase over its 2022 earnings that were of -$11.87 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 | $11.75 M | -199.05% |
2022 | -$11.87 M | -40.38% |
2021 | -$19.91 M | -732.31% |
2020 | $3.14 M | -130.53% |
2019 | -$10.31 M | 189.85% |
2018 | -$3.56 M | -95.29% |
2017 | -$75.55 M | 308.12% |
2016 | -$18.52 M | -32.37% |
2015 | -$27.38 M | 10.11% |
2014 | -$24.86 M | -7.59% |
2013 | -$26.9 M | |
2011 | -$31.15 M | -19.39% |
2010 | -$38.65 M | 20.87% |
2009 | -$31.97 M | 32.26% |
2008 | -$24.18 M | -5.46% |
2007 | -$25.57 M | |
2004 | -$0.17 M | 12.35% |
2003 | -$0.15 M | -11.1% |
2002 | -$0.17 M | -57.03% |
2001 | -$0.39 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pfizer PFE | $0.89 B | 9,077.15% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $0.47 B | 4,794.82% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | -$0.15 B | -1,548.39% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $0.18 B | 1,817.92% | ๐ฎ๐ฑ Israel |